Osteoclastogenic capacity of peripheral blood mononuclear cells is not different between women with and without osteoporosis

Bone

Volumn 95, Issue , 2017, Pages 108-114

  Koek, W N H ^a   van der Eerden, B C J ^a   Alves, R D A M ^a   van Driel, M ^a   Schreuders Koedam, M ^a   Zillikens, M C ^a   van Leeuwen, J P T M ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Deoxypyridinoline; Fractures; Osteoclasts; Osteoporosis; Peripheral blood mononuclear cells

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CATHEPSIN K; DEOXYPYRIDINOLINE; GLUCOCORTICOID; MEMBRANE PROTEIN; RNA;

AGED; ARTICLE; BODY HEIGHT; BODY MASS; BODY WEIGHT; BONE DENSITY; CELL DIFFERENTIATION; CELL FUNCTION; CLINICAL ARTICLE; CONTROLLED STUDY; CTSK GENE; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LUMBAR SPINE; OSTEOCLAST; OSTEOCLASTOGENESIS; OSTEOLYSIS; OSTEOPOROSIS; PERIPHERAL BLOOD MONONUCLEAR CELL; POSTMENOPAUSE; PROTEIN EXPRESSION; SPINE FRACTURE; TM7SF4 GENE; VERY ELDERLY; BLOOD; BONE DEVELOPMENT; CASE CONTROL STUDY; FRAGILITY FRACTURE; METABOLISM; MONONUCLEAR CELL; PATHOLOGY;

AGED; BONE RESORPTION; CASE-CONTROL STUDIES; CELL DIFFERENTIATION; FEMALE; HUMANS; LEUKOCYTES, MONONUCLEAR; OSTEOCLASTS; OSTEOGENESIS; OSTEOPOROSIS; OSTEOPOROTIC FRACTURES;

EID: 84997107948     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2016.11.010     Document Type: Article

References (23)

1. [1] Poos, G.A., MJJC, Prevalentie en incidentie naar leeftijd en geslacht. http://www.nationaalkompas.nl/gezondheid-en-ziekte/ziekten-en-aandoeningen/bewegingsstelsel-en-bindweefsel/osteoporose/prevalentie-en-incidentie-naar-leeftijd-en-geslacht/>, 2009.
2. [2] Van der Klift, M., De Laet, C.E., McCloskey, E.V., Hofman, A., Pols, H.A., The incidence of vertebral fractures in men and women: the Rotterdam study. J. Bone Miner. Res. 17:6 (2002), 1051–1056.
3. [3] Agrawal, A., Gallagher, J.A., Gartland, A., Human osteoclast culture and phenotypic characterization. Methods Mol. Biol. 806 (2012), 357–375.
4. [4] D'Amelio, P., Grimaldi, A., Pescarmona, G.P., Tamone, C., Roato, I., Isaia, G., Spontaneous osteoclast formation from peripheral blood mononuclear cells in postmenopausal osteoporosis. FASEB J. 19:3 (2005), 410–412.
5. [5] Jevon, M., Hirayama, T., Brown, M.A., Wass, J.A., Sabokbar, A., Ostelere, S., Athenasou, N.A., Osteoclast formation from circulating precursors in osteoporosis. Scand. J. Rheumatol. 32:2 (2003), 95–100.
6. [6] Underwood, J.C., Melick, R.A., Loomes, R.S., Dangerfield, V.M., Crawford, A., Coulton, L., Ingleton, P.M., Martin, T.J., Structural and functional correlations in parathyroid hormone responsive transplantable osteogenic sarcomas. Eur. J. Cancer 15:9 (1979), 1151–1158.
7. [7] Hofman, A., Brusselle, G.G., Darwish Murad, S., van Duijn, C.M., Franco, O.H., Goedegebure, A., Ikram, M.A., Klaver, C.C., Nijsten, T.E., Peeters, R.P., Stricker, B.H., Tiemeier, H.W., Uitterlinden, A.G., Vernooij, M.W., The Rotterdam study: 2016 objectives and design update. Eur. J. Epidemiol. 30:8 (2015), 661–708.
8. [8] Feng, X., McDonald, J.M., Disorders of bone remodeling. Annu. Rev. Pathol. 6 (2011), 121–145.
9. [9] Stolk, L., van Meurs, J.B., Arp, P.P., Hofman, A., Pols, H.A., Uitterlinden, A.G., The RIZ Pro704 insertion-deletion polymorphism, bone mineral density and fracture risk: the Rotterdam study. Bone 42:2 (2008), 286–293.
10. [10] van der Eerden, B.C., Hoenderop, J.G., de Vries, T.J., Schoenmaker, T., Buurman, C.J., Uitterlinden, A.G., Pols, H.A., Bindels, R.J., van Leeuwen, J.P., The epithelial Ca2 + channel TRPV5 is essential for proper osteoclastic bone resorption. Proc. Natl. Acad. Sci. U. S. A. 102:48 (2005), 17507–17512.
11. [11] Bruedigam, C., Koedam, M., Chiba, H., Eijken, M., van Leeuwen, J.P., Evidence for multiple peroxisome proliferator-activated receptor gamma transcripts in bone: fine-tuning by hormonal regulation and mRNA stability. FEBS Lett. 582:11 (2008), 1618–1624.
12. [12] Khosla, S., Melton, L.J. 3rd, Riggs, B.L., The unitary model for estrogen deficiency and the pathogenesis of osteoporosis: is a revision needed?. J. Bone Miner. Res. 26:3 (2011), 441–451.
13. [13] Ivaska, K.K., Gerdhem, P., Vaananen, H.K., Akesson, K., Obrant, K.J., Bone turnover markers and prediction of fracture: a prospective follow-up study of 1040 elderly women for a mean of 9 years. J. Bone Miner. Res. 25:2 (2010), 393–403.
14. [14] Garnero, P., Sornay-Rendu, E., Chapuy, M.C., Delmas, P.D., Increased bone turnover in late postmenopausal women is a major determinant of osteoporosis. J. Bone Miner. Res. Off. J. Am. Soc. Bone Miner. Res. 11:3 (1996), 337–349.
15. [15] Mezquita-Raya, P., Munoz-Torres, M., Luna, J.D., Luna, V., Lopez-Rodriguez, F., Torres-Vela, E., Escobar-Jimenez, F., Relation between vitamin D insufficiency, bone density, and bone metabolism in healthy postmenopausal women. J. Bone Miner. Res. 16:8 (2001), 1408–1415.
16. [16] Harris, S.S., Soteriades, E., Dawson-Hughes, B., Framingham Heart, S., S. Boston Low-Income Elderly Osteoporosis, Secondary hyperparathyroidism and bone turnover in elderly blacks and whites. J Clin Endocrinol Metab 86:8 (2001), 3801–3804.
17. [17] Sambrook, P.N., Chen, J.S., March, L.M., Cameron, I.D., Cumming, R.G., Lord, S.R., Schwarz, J., Seibel, M.J., Serum parathyroid hormone is associated with increased mortality independent of 25-hydroxy vitamin D status, bone mass, and renal function in the frail and very old: a cohort study. J. Clin. Endocrinol. Metab. 89:11 (2004), 5477–5481.
18. [18] Zhang, C., Dou, C.E., Xu, J., Dong, S., DC-STAMP, the key fusion-mediating molecule in osteoclastogenesis. J. Cell. Physiol. 229:10 (2014), 1330–1335.
19. [19] Zhao, Q., Jia, Y., Xiao, Y., Cathepsin K: a therapeutic target for bone diseases. Biochem. Biophys. Res. Commun. 380:4 (2009), 721–723.
20. [20] Hemingway, F., Cheng, X., Knowles, H.J., Estrada, F.M., Gordon, S., Athanasou, N.A., In vitro generation of mature human osteoclasts. Calcif. Tissue Int. 89:5 (2011), 389–395.
21. [21] Riggs, B.L., Melton, L.J. 3rd, Involutional osteoporosis. N. Engl. J. Med. 314:26 (1986), 1676–1686.
22. [23] D'Amelio, P., Grimaldi, A., Di Bella, S., Tamone, C., Brianza, S.Z., Ravazzoli, M.G., Bernabei, P., Cristofaro, M.A., Pescarmona, G.P., Isaia, G., Risedronate reduces osteoclast precursors and cytokine production in postmenopausal osteoporotic women. J. Bone Miner. Res. 23:3 (2008), 373–379.
23. [24] Black, D.M., Schwartz, A.V., Ensrud, K.E., Cauley, J.A., Levis, S., Quandt, S.A., Satterfield, S., Wallace, R.B., Bauer, D.C., Palermo, L., Wehren, L.E., Lombardi, A., Santora, A.C., Cummings, S.R., Effects of continuing or stopping alendronate after 5 years of treatment: the fracture intervention trial long-term extension (FLEX): a randomized trial. JAMA 296:24 (2006), 2927–2938.